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Abstract
Breast cancer, the most common spontaneous malignancy diagnosed in women,
is a classical model of hormone dependency as it is associated with prolonged
exposure to female hormones. Different cytoplasmic proteins are important in
the transformation of a normal cell to an invasive tumor cell, and these include
vimentin and Notch. To investigate the importance of these two genes and
proteins in breast carcinogenesis, we used an in vitro breast cancer model
system, in which an immortalized human breast epithelial cell line, MCF-10F,
was malignantly transformed by exposure to low doses of high linear energy
transfer α particle (150 keV/μm) radiation and subsequent growth in the presence
or absence of 17β-estradiol. This model consisted of human breast epithelial
cells in different stages of transformation: i) a parental cell line (MCF-10F), ii)
an Estrogen cell line (MCF-l0F continuously grown with estradiol at 10<sup>-8</
sup>), iii)malignant and non-tumorigenic cell line (Alpha3), iv)...
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Abstract. Breast cancer, the most common spontaneous 
malignancy diagnosed in women, is a classical model of 
hormone dependency as it is associated with prolonged expo-
sure to female hormones. Different cytoplasmic proteins are 
important in the transformation of a normal cell to an invasive 
tumor cell, and these include vimentin and Notch. To investi-
gate the importance of these two genes and proteins in breast 
carcinogenesis, we used an in vitro breast cancer model system, 
in which an immortalized human breast epithelial cell line, 
MCF-10F, was malignantly transformed by exposure to low 
doses of high linear energy transfer α particle (150 keV/µm) 
radiation and subsequent growth in the presence or absence of 
17β-estradiol. This model consisted of human breast epithelial 
cells in different stages of transformation: i) a parental cell line 
(MCF-10F), ii) an Estrogen cell line (MCF-l0F continuously 
grown with estradiol at 10-8), iii) a malignant and non-tumor-
igenic cell line (Alpha3), iv) a malignant and tumorigenic cell 
line (Alpha5) and v) a Tumor2 cell line derived from a xenograft 
of the Alpha5 cell line injected into nude mice. Vimentin and 
Notch showed greater expression in the Alpha5 and Tumor2 
cell lines compared with that in the non-tumorigenic cell lines, 
MCF-10F, Estrogen and Alpha3. In the present study, positive 
staining for vimentin was found in 21% of cases. Vimentin and 
Notch protein expression was negative in noninvasive ductal 
carcinoma biopsies from breast cancer patients. However, 
positive cell expression was observed in invasive ductal carci-
noma biopsies. These biomarkers can be considered important 
indicators of breast cancer progression and can be added to the 
diagnostic panel when overall survival is a primary end-point. 
Introduction
Breast cancer, the most common spontaneous malignancy 
diagnosed in women, is a classical model of hormone depen-
dency. There is evidence that breast cancer risk is associated 
with prolonged exposure to female hormones, as the onset of 
menarche, late menopause and hormone replacement therapy 
are associated with greater cancer incidence (1). The progres-
sion of breast cancer follows a complex multi-step process that 
depends on various exogenous (diet and breast irradiation) and 
endogenous (age, hormonal imbalances, proliferative lesions 
and family history of breast cancer) factors (2-4). Breast cancer 
is a complex disease in which numerous genetic aberrations 
occur. Cellular and molecular changes that occur during the 
development of cancer can be mediated by a range of endog-
enous and environmental stimuli. On the basis of the currently 
accepted view of breast cancer as a multi-step process, it is 
possible that specific abnormalities may be an essential part of 
the transformation of a normal cell to an invasive tumor cell.
Different cytoplasmic proteins are key in the trans-
formation of a normal cell to an invasive tumor cell and 
among these, vimentin is particularly important. It is one of 
the cytoplasmic intermediate filament proteins, which are 
the major components of the cytoskeleton normally found 
in embryonic or mesenchymal stem cells (5,6). However, 
vimentin is frequently expressed in neoplastic cells with 
metastatic properties, including breast cancer cells (7,8). It is 
a 57‑kDa intermediate filament protein, which forms a part of 
the cytoskeleton. Expression of vimentin and cytokeratins has 
also been described in breast carcinomas. Hendrix et al (9) 
demonstrated that the co-expression of vimentin and keratin 
intermediate filaments in human breast cancer cells results in 
phenotypic inter-conversion and increased invasive behavior.
Another important gene, Notch, is also pivotal in this 
context. This gene is expressed in a variety of tissues, indi-
cating that it is involved in multiple signaling pathways (10-14). 
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It is either overexpressed or rearranged in human tumors, such 
as is the case with the 280- to 330-kDa Notch protein (14). 
The LIN‑12/Notch family of transmembrane receptors is 
believed to be central to development by regulating cell fate 
decisions (10-13). Notch signals are involved in the develop-
ment and maintenance of normal tissues that are recapitulated 
in different forms of cancer (14,15). Notch can either promote 
or limit tumor growth, depending on the tumor type, through 
differentiation, cellular metabolism, cell cycle progression, 
angiogenesis and possibly self-renewal and immune func-
tion (16,17,19,20). The Notch signaling pathway is critical 
in cell fate decisions, tissue patterning and morphogenesis, 
and is hence regarded as a developmental pathway. However, 
problems with this pathway can contribute to cellular transfor-
mation and tumorigenesis.
The expression of Notch receptors and their down-
stream target genes is upregulated in primary human 
melanomas (15,16), and the expression of constitutively active 
Notch1 promotes melanoma progression (15,17). These onco-
genic effects correlate with the activation of Wnt signaling 
in melanoma cells (15), which promotes the expression of 
adhesion molecules such as N-cadherin (17) through the tran-
scription factor TCF/LEF (15). Notch has also been implicated 
in the pathogenesis of other solid tumors, such as medulloblas-
toma (18,19) and ovarian cancer (20), and the number of known 
neoplasms involving some alteration in Notch signaling is 
increasing. The aim of the present study was to assess whether 
vimentin and Notch gene and protein expression are altered 
in breast cancer progression. The importance of vimentin 
expression was analyzed by identifying cases of breast cancer 
with poor prognosis and comparing vimentin and Notch as 
biomarkers required for prognosis in breast cancer patients.
Materials and methods
Cell lines. MCF-10F cells were grown in DMEM/F-12 (1:1) 
medium supplemented with antibiotics [100 U/mI penicillin, 
100 µg/ml streptomycin and 2.5 µg/ml amphotericin B 
(all from Life Technologies, Grand Island, NY, USA)] and 
10 µg/m of 5% equine serum (Biofluids, Rockville, MD, USA), 
0.5 µg/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO, 
USA) and 0.02 µg/ml epidermal growth factor (Collaborative 
Research, Bedford, MA, USA) (21). An in vitro experimental 
breast cancer model (Alpha model) (22), developed by 
exposing the immortalized human breast epithelial MCF-10F 
cell line to low doses of high linear energy transfer α particle 
radiation (150 keV/µm) and subsequent growth in the presence 
or absence of 17β-estradiol, was used in this study. This model 
consisted of human breast epithelial cells in different stages of 
transformation: i) a control cell line (MCF-10F), ii) an Estrogen 
cell line [(MCF-l0F continually treated with estradiol at 
10-8 M (Sigma-Aldrich)], iii) a malignant but non-tumorigenic 
cell line (Alpha3), iv) a malignant and tumorigenic cell line 
(Alpha5) and v) a Tumor2 cell line derived from cells origi-
nating from a tumor after injection of the Alpha5 cell line into 
nude mice. A total of 21 female CB17 SCID mice (Taconic, 
Germatown, NY, USA) and nude mice (Harlam Sprague 
Dawley, Indianapolis, IN, USA) (age, 1 year) were used in 
these studies. Each animal was injected subcutaneously at two 
different sites with 8x106 cells in 0.2 ml saline in the fat pad 
of the right and left side of the abdominal mammary gland. 
The study was approved by the ethics committee of Columbia 
University Medical Center (New York, NY, USA)
Pathological analysis. Formalin‑fixed, paraffin‑embedded, 
noninvasive and invasive ductal and lobular carcinomas were 
obtained from the archives of the Pathology Department of 
Dr Gustavo Fricke Hospital, Viña del Mar, Valparaíso, Chile. 
Patients had undergone surgery (total mastectomy with axillary 
lymph node dissection) between 1997 and 2001. The median 
patient age at surgery was 56 years (range, 25-92 years). The 
primary pathological diagnosis was confirmed by hematoxylin 
and eosin staining. All operative and pathological reports 
were reviewed to confirm disease stage. Sections of 2 µm 
were cut and mounted onto polylysine-coated slides, and 
stained for vimentin and Notch protein expression. The study 
was approved by the ethics committee of Dr. Gustavo Fricke 
Hospital of Viña del Mar (Valparaiso, Chile).
Immunoperoxidase staining. Protein expression was 
evaluated as previously described (22-24). Exponentially 
growing cell lines were plated on a glass chamber slide 
(Nunc Inc., Naperville, IL, USA) at a density of 1x104 
cells/ml of medium and allowed to grow for 2-3 days until 
they reached 70% confluence (21). The cells were fixed with 
buffered paraformaldehyde at room temperature, incubated 
with 1% H2O2 in methanol to block endogenous peroxidase 
and washed twice with buffer solution. Cell cultures were 
subsequently covered with normal horse serum for 30 min 
at RT and incubated with anti-rabbit monoclonal antibody 
(vimentin: C-20, sc 7557 and Notch 4: C-19, sc 8644) (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a 1:500 
dilution at 4˚C overnight, and then incubated for 45 min with 
diluted biotinylated secondary antibody solution (Vector 
Laboratories, Burlingame, CA, USA) and Vectastin Elite 
ABC Reagent (Vector Laboratories). The experiments were 
repeated three times in cells with identical passages in vitro. 
The number of immune-reactive cells (50 cells/field) was 
counted in several randomly selected microscopy fields 
(x400) per sample using an optical microscope (CX31; 
Olympus Corporation, Tokyo, Japan). Ten fields were counted 
for each cell line. 
Inmunofluorescent staining. Protein expression was evalu-
ated by immunofluorescent staining and confocal microscopy 
as previously described (22,23). Cells were viewed on Zeis 
Axiovert 100 TV microscope (Carl Zeiss, Thornwood, NY, 
USA) using a 40X 11.3 NA objective lens equipped with a 
laser scanning confocal attachment (LSM 410, Carl Zeiss). 
A semi-quantitative estimation of the area and the intensity 
of the staining of the cells present in the culture dishes 
were performed based on the relative staining of the protein 
expressed by the controls and transformed cells.
Fluorescent‑labeled probe preparation for micro‑
array analysis. The poly(A) mRNA from normal, 
radiation- and estrogen-treated breast cell lines was isolated 
using a QIA-direct-mRNA isolation kit (Qiagen, Inc., 
Valencia, CA, USA). Fluorescent-labeled cDNA was prepared 
from 1 µg of each of these poly(A) mRNA samples by 
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using oligo dT-primed polymerization and a Superscript II 
reverse transcriptase kit (Life Technologies) in the presence 
of either Cy3- or Cy5-labeled dCTP, following the usual 
procedure (http://cmgm.stanford.edu/pbrown/protocols/). The 
appropriate Cy3- and Cy5-labeled probes were pooled and 
hybridized to microarray glass coverslips for 16 h at 65˚C and 
then washed with high stringency for analysis. 
Affymetrix HG‑U133A Plus 2.0 GeneChip microarray gene 
expression analysis. The breast cancer model (Alpha model) 
containing i) MCF-10F, ii) Estrogen, (iii) Alpha3, iv) Alpha5 
and v) Tumor2 cell lines was analyzed for gene expres-
sion using Affymetrix U133A oligonucleotide microarray 
(Affymetrix, Santa Clara, CA, USA), which contains 14,500 
genes. Arrays were quantitatively analyzed for gene expres-
sion using the Affymetrix GeneChip Operating Software, with 
dual global scaling option in a Genes@Work software plat-
form of discovery algorithm, Structural Pattern Localization 
Analysis by Sequential Histograms, and a false discovery rate 
of 0.05 (25,26).
Results
Phenotypic and molecular analysis of vimentin expression 
in breast cancer progression model. The established breast 
cancer model (22) has been shown to exhibit important pheno-
typic characteristics of breast carcinogenesis. The normal 
cell line, MCF-10F, did not exhibit any of the features that 
characterize malignant cells, such as anchorage-independent 
growth in soft agar, invasion and tumor growth in nude 
mice (22,24). The Alpha3 cell line formed colonies in soft 
agar and had invasive capabilities, but failed to form tumors in 
the immuno-suppressed mice. However, the Alpha5 cell line 
induced mammary gland tumors in the animals and metastasis 
in the liver, lung and kidneys after injection. This cell line gave 
rise to the Tumor2 cell line after removal of the mammary 
tumor, digestion in in vitro conditions and culture for many 
passages.
The analysis of immunoperoxidase (Fig. 1A) and immuno-
fluorescence (Fig. 1B) data obtained in relation to the relative 
vimentin expression in MCF-10F, Estrogen, Alpha3, Alpha5 
and Tumor2 cell lines indicated that such expression was signifi-
cantly greater (P<0.05) in the Tumor2, Alpha3 and Alpha5 cell 
lines, when compared with the MCF-10F and Estrogen cell 
lines. Genes that were identified to be differentially expressed 
between cell lines of this model were also studied. Histogram 
plots of the differential expression of vimentin and Notch genes 
in these cell lines were detected by gene chip array. Results 
of pairwise comparisons of cell lines examined for vimentin 
protein expression were analyzed with the following pairs of cell 
lines: MCF-10F/Estrogen, MCF-10F/Alpha3, Estrogen/Alpha5, 
Alpha3/Alpha5, Alpha5/Tumor2 and Alpha 3/Tumor2 (Fig. 1C). 
Results of the pairwise comparisons did not reveal any altera-
tion in vimentin gene expression between the MCF-10F and 
Estrogen cell lines, while there was an almost nine‑ and five‑fold 
alteration in the MCF-10F/Alpha3 and Estrogen/Alpha5 combi-
nations, respectively. There were six- and four- fold changes in 
gene expression between the Alpha5 and Tumor2 cell lines, and 
Alpha3 and Tumor2 cell lines, respectively. 
Results of pairwise comparisons of cell lines examined 
for Notch gene expression are shown in Fig. 1D. Results of 
the same pairs of cell lines were analyzed, revealing no 
alteration in Notch gene expression between the MCF-10F 
and Estrogen cell lines, Estrogen and Alpha5 cell lines, and 
Alpha3 and Alpha5 cell lines. By contrast, there was an 
almost ten- and fourteen-fold alteration in the Alpha5/Tumor2 
and Alpha3/Tumor2 combinations, respectively, with higher 
expression in Alpha3 and Alpha5 than in Tumor2. 
Figure 1. Bars represent the average and standard error of vimentin protein expression by (A) peroxidase and (B) immunofluorescent techniques of the 
MCF-10F, Estrogen, Alpha3, Alpha5 and Tumor2 cell lines. The primary antibodies used were mouse monoclonal antibodies (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). Fold change of (C) vimentin and (D) Notch gene expression. Gene expression from scatter plots of the following pairwise comparative 
studies of cell lines: MCF-10F/E (1), MCF-10F/Alpha3 (2), E/Alpha5 (3), Alpha3/Alpha5 (4), Alpha 3/Tumor2 (5) and Alpha5/Tumor2 (6).
  A   B
  C   D
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Figure 3. Notch protein expression of (A) MCF-10F; (B) Alpha5; (C) Tumor2 cell lines. Biopsy specimens containing (D) ductal carcinoma and (E and 
F) invasive ductal carcinoma determined by immunoperoxidase technique (magnification, x400).
Figure 2. Representative images of vimentin protein expression stained by (A‑C) immunoperoxidase and (D‑F) immunofluorescent techniques in a breast cancer 
cell model. Biopsy specimens containing (G‑I) ducts and lobules, and (J‑L) invasive carcinoma determined by inmunoperoxidase techniques (magnification, x400).
  A   B   C
  D   E   F
  G   H   I
  J   K   L
  A   B   C
  D   E   F
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Vimentin protein expression in breast cancer model and 
breast biopsy specimens. Representative images of vimentin 
protein expression, in which greater expression was observed 
in the Alpha5 and Tumor2 cell lines compared with that in 
the control MCF-10F cell line, can be observed in immuno-
peroxidase (Fig. 2A‑C) and immunofluorescence (Fig. 2D‑F) 
studies. Biopsy specimens were also analyzed for vimentin 
protein expression to analyze progression in breast cancer. 
Fig. 2G-I shows representative tissues of vimentin protein 
expression in ducts found in sections of biopsies from breast 
cancer patients, as determined by immunoperoxidase staining. 
This expression was negative in noninvasive ductal carcinoma 
and breast epithelial lesions surrounding the primary tumors, 
ductal and lobular hyperplasia, and microcytes. By contrast, 
this expression was positive in breast specimens with invasive 
characteristics, as shown in Fig. 2J-L. Positive staining for 
vimentin was found in 21% of cases.
Notch protein expression in breast cancer model and breast 
biopsy specimens. In the present study, non-malignant and 
malignant cell lines from the model were used to analyze Notch 
protein expression. Fig. 3A-C shows higher Notch protein 
expression in the Alpha5 and Tumor2 cell lines compared 
with that in the control MCF-10F cell line, as determined by 
immunoperoxidase staining. Samples from biopsy specimens 
showed negative Notch protein expression in noninvasive 
ductal carcinomas. However, positive cell expression was 
observed in those tissues with cells from invasive ductal 
carcinomas (Fig. 3D-F), particularly in invasive isolated tumor 
cells. Positive staining for Notch was found in 25% of cases.
Discussion
The main purpose of the present study was to assess the prog-
nostic value of the markers vimentin and Notch. Identification 
of factors involved in cell proliferation and transformation 
has been facilitated by studies using various human epithelial 
cell lines. The analysis of immunoperoxidase and immuno-
fluorescence data obtained in relation to the relative vimentin 
expression indicated that such expression was significantly 
greater in Tumor2 and Alpha5 when compared with MCF-10F, 
Estrogen and Alpha3 cell lines. 
Results of pairwise comparisons of vimentin gene 
expression in the different cell lines indicated that there 
was no alteration in vimentin gene expression between 
the MCF-10F and Estrogen cell lines, while there was an 
almost nine‑ and five‑fold alteration in the MCF‑10F/Alpha3 
and Estrogen/Alpha5 combinations, respectively. There 
were six- and four-fold changes in gene expression between 
Alpha5 and Tumor2, and Alpha3 and Tumor2, respectively. 
Results of the same pairs of cell lines analyzed for Notch gene 
expression indicated that there was no alteration between the 
MCF-10F and Estrogen, Estrogen and Alpha5, and Alpha3 
and Alpha5 cell lines. By contrast, there was an almost 
ten- and fourteen- fold alteration in the Alpha5/Tumor2 and 
Alpha3/Tumor2 combinations, respectively, with higher 
expression in Alpha3 and Alpha5 than in Tumor2 cells. 
Vimentin protein expression in ducts in sections of biopsies 
from breast cancer patients was found to be negative for 
noninvasive ductal carcinoma, but positive for ductal carci-
noma with invasive characteristics. Vimentin-reactive cells 
in benign and malignant breast tissue have been described in 
many studies (26-29). These studies reported that vimentin 
expression appeared to be associated with poor prognosis in 
node-negative ductal breast carcinomas, and that vimentin was 
preferentially expressed in human breast carcinomas with low 
levels of estrogen receptors. Gene expression patterns of breast 
carcinomas distinguished tumor subclasses with clinical 
implications (30). A possible association was found between 
the clinically aggressive behavior of tumors (28,29) and 
estrogen receptor negativity (31,32), high Ki-67 levels (32) and 
poor differentiation of tumors with high-grade and positive 
vimentin protein expression. Domagala et al (29) reported that 
vimentin was preferentially expressed in high-grade ductal 
and medullary, but not in lobular, breast carcinomas. Other 
data showed that more invasive breast cancer lines expressed 
vimentin, indicating its usefulness in identifying cases with 
poorer prognosis (28,29). 
Vimentin is known to be selectively expressed in aggressive 
breast cancer cell lines (9). Elevated vimentin expression levels 
correlate well with upregulated migration and invasion of 
cancer cells (9,26). Sommers et al (27) showed that transfection 
of noninvasive human breast cancer cell lines, such as MCF7, 
with the vimentin gene led to accelerated invasiveness. The 
authors also reported vimentin rather than keratin expression 
in certain hormone-independent breast cancer cell lines, and in 
oncogene-transformed mammary epithelial cells. The possible 
association of vimentin with the clinically aggressive behavior 
of tumors described by others (7,28-32) may be explained by 
the correlation of vimentin expression with a lack of steroid 
receptors and poor differentiation of cancer. Gilles et al (31) 
also found vimentin expression in cervical carcinomas was 
associated with invasive and migratory potential.
Thus, we can suggest an improved indicator of breast 
cancer progression by adding vimentin to the diagnostic panel 
when overall survival is a primary end-point. In the present 
study, positive staining for vimentin was found in 21% of 
cases, which is in line with previous findings (32). Therefore, 
vimentin expression appears to predict survival in ductal 
breast carcinoma.
Notch protein expression was also higher in the Alpha5 
and Tumor2 cell lines in comparison with that in the control 
MCF-10F cell line. When samples from biopsy specimens were 
analyzed for Notch protein expression, negative cells were found 
in noninvasive ductal carcinomas while positive cells were found 
in invasive ductal carcinomas. It has been reported that the 
Notch pathway is required for the establishment of embryonic 
hematopoietic stem cells (33), and it has been implicated in the 
maintenance of several types of normal cell populations (34-36). 
The effects of Notch on cells include increased survival or death, 
proliferation or growth arrest and commitment to, or blockage 
of, differentiation. These different outcomes are mediated 
through a novel signaling pathway in which Notch receptors on 
the cell surface give rise to a nuclear transcriptional activation 
complex. Studies on Notch are related to the understanding of 
how this pathway yields several outcomes. It has been proposed 
that Notch may serve as an oncogene or tumor suppressor, a 
repressor or inducer of terminal differentiation, or a cancer stem 
cell factor. Studies on the multifaceted role of Notch in cancer 
indicate a possible therapeutic implication. Notch signaling is 
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frequently deregulated in breast cancer, and hyperactivation of 
Notch contributes to the tumor process. Notch has been shown 
to be involved in the controlled proliferation and migration of 
vascular endothelial cells, as well as in the integration of Notch 
and Wnt signaling, as observed in hematopoietic stem cell 
maintenance (34). Guentchev and McKay (35) observed that 
Notch controlled the proliferation and differentiation of stem 
cells in a dose-dependent manner. It has also been suggested 
that Notch acts as a transducer molecule for developmental 
processes. Stylianou et al (36) observed aberrant activation of 
Notch signaling in human breast cancer. 
Estrogens are known to regulate the proliferation of breast 
cancer cells and to alter their phenotypic properties; the gene 
networks and pathways through which estrogenic hormones regu-
late these events have also been considered (37). We used global 
gene expression profiling by Affymetrix GeneChip microarray 
analysis to identify genes altered by the presence of estradiol in 
an MCF-10F human breast cancer model. Of the >14,000 genes 
analyzed, over 300 showed a pattern of either up- or downregula-
tion. We observed a general upregulation of positive proliferation 
regulators, including multiple growth factors, genes involved in 
cell cycle progression and regulatory factor-receptor loops, and 
a downregulation of transcriptional repressors and anti-prolif-
erative and pro-apoptotic genes, including BCL2 and TGF‑β 
family growth inhibitory factors. The present study highlights 
the diverse gene networks and metabolic and cell regulatory 
pathways through which this hormone operates to achieve its 
widespread effects on breast cancer cells. 
It can be concluded that vimentin and Notch gene and 
protein expression are altered in breast cancer progression, 
thereby helping to identify cases of breast cancer with poor 
prognosis and complementing those biomarkers required for 
assessing the prognosis of breast cancer patients.
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